NO308610B1 - Ribozymer for anvendelse som midler for behandling av planter, fremgangsmÕte for fremstilling derav, og preparater omfattende slike ribozymer - Google Patents
Ribozymer for anvendelse som midler for behandling av planter, fremgangsmÕte for fremstilling derav, og preparater omfattende slike ribozymer Download PDFInfo
- Publication number
- NO308610B1 NO308610B1 NO902661A NO902661A NO308610B1 NO 308610 B1 NO308610 B1 NO 308610B1 NO 902661 A NO902661 A NO 902661A NO 902661 A NO902661 A NO 902661A NO 308610 B1 NO308610 B1 NO 308610B1
- Authority
- NO
- Norway
- Prior art keywords
- rna
- sequence
- ribozyme
- compound
- stated
- Prior art date
Links
- 108091092562 ribozyme Proteins 0.000 title claims description 202
- 108090000994 Catalytic RNA Proteins 0.000 title claims description 196
- 102000053642 Catalytic RNA Human genes 0.000 title claims description 194
- 238000000034 method Methods 0.000 title claims description 32
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000011282 treatment Methods 0.000 title description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 168
- 239000002773 nucleotide Substances 0.000 claims description 51
- 125000003729 nucleotide group Chemical group 0.000 claims description 46
- 108091028664 Ribonucleotide Proteins 0.000 claims description 41
- 239000002336 ribonucleotide Substances 0.000 claims description 41
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 108020004414 DNA Proteins 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 25
- 238000012546 transfer Methods 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 18
- 238000013518 transcription Methods 0.000 claims description 15
- 230000035897 transcription Effects 0.000 claims description 15
- 108091034117 Oligonucleotide Proteins 0.000 claims description 13
- 108091027075 5S-rRNA precursor Proteins 0.000 claims description 12
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 10
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 10
- 230000000415 inactivating effect Effects 0.000 claims description 10
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 6
- 108020000999 Viral RNA Proteins 0.000 claims description 4
- 210000004102 animal cell Anatomy 0.000 claims description 4
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 61
- 238000005520 cutting process Methods 0.000 description 61
- 230000000694 effects Effects 0.000 description 53
- 239000013612 plasmid Substances 0.000 description 43
- 230000003197 catalytic effect Effects 0.000 description 36
- 239000012634 fragment Substances 0.000 description 32
- 238000003776 cleavage reaction Methods 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000000758 substrate Substances 0.000 description 20
- 241000196324 Embryophyta Species 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 18
- 230000007017 scission Effects 0.000 description 18
- 241000726311 Citrus exocortis viroid Species 0.000 description 17
- 101150055766 cat gene Proteins 0.000 description 17
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 230000000692 anti-sense effect Effects 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 108010093099 Endoribonucleases Proteins 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- 102100030011 Endoribonuclease Human genes 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 239000003184 complementary RNA Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 108020005544 Antisense RNA Proteins 0.000 description 6
- 108020005543 Satellite RNA Proteins 0.000 description 6
- 241001428638 Tobacco ringspot virus satellite RNA Species 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 108020001778 catalytic domains Proteins 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 241000724705 Lucerne transient streak virus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 101710137500 T7 RNA polymerase Proteins 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 210000001938 protoplast Anatomy 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 241000726301 Avocado sunblotch viroid Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 241000724703 Subterranean clover mottle virus Species 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 241000701489 Cauliflower mosaic virus Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 3
- 241000724704 Solanum nodiflorum mottle virus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100268665 Caenorhabditis elegans acc-1 gene Proteins 0.000 description 2
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 2
- 241000269333 Caudata Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 241001452028 Escherichia coli DH1 Species 0.000 description 2
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 101100442582 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) spe-1 gene Proteins 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 2
- 108020004487 Satellite DNA Proteins 0.000 description 2
- 241000723677 Tobacco ringspot virus Species 0.000 description 2
- 241000724701 Velvet tobacco mottle virus Species 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 241000726445 Viroids Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 230000002358 autolytic effect Effects 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000010310 bacterial transformation Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000002245 ribonucleolytic effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- GGKNTGJPGZQNID-UHFFFAOYSA-N (1-$l^{1}-oxidanyl-2,2,6,6-tetramethylpiperidin-4-yl)-trimethylazanium Chemical compound CC1(C)CC([N+](C)(C)C)CC(C)(C)N1[O] GGKNTGJPGZQNID-UHFFFAOYSA-N 0.000 description 1
- 102100039601 ARF GTPase-activating protein GIT1 Human genes 0.000 description 1
- 101710194905 ARF GTPase-activating protein GIT1 Proteins 0.000 description 1
- 102100039602 ARF GTPase-activating protein GIT2 Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 101710081758 High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241000208133 Nicotiana plumbaginifolia Species 0.000 description 1
- 241000228669 Nicotiana velutina Species 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 1
- 108010046983 Ribonuclease T1 Proteins 0.000 description 1
- 108091006231 SLC7A2 Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000248384 Tetrahymena thermophila Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- -1 ligations Proteins 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108090000446 ribonuclease T(2) Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
- A01N57/10—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds
- A01N57/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing heterocyclic radicals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/60—Isolated nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Pest Control & Pesticides (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPI591187 | 1987-12-15 | ||
| AUPI995088 | 1988-08-19 | ||
| AUPJ035388 | 1988-09-09 | ||
| AUPJ130488 | 1988-11-04 | ||
| AUPJ133388 | 1988-11-07 | ||
| PCT/AU1988/000478 WO1989005852A1 (en) | 1987-12-15 | 1988-12-14 | Ribozymes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO902661D0 NO902661D0 (no) | 1990-06-14 |
| NO902661L NO902661L (no) | 1990-08-14 |
| NO308610B1 true NO308610B1 (no) | 2000-10-02 |
Family
ID=27507391
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO902661A NO308610B1 (no) | 1987-12-15 | 1990-06-14 | Ribozymer for anvendelse som midler for behandling av planter, fremgangsmÕte for fremstilling derav, og preparater omfattende slike ribozymer |
| NO20000369A NO312105B1 (no) | 1987-12-15 | 2000-01-25 | Fremgangsmåte for fremstilling av ribozymer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000369A NO312105B1 (no) | 1987-12-15 | 2000-01-25 | Fremgangsmåte for fremstilling av ribozymer |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP0640688A1 (da) |
| JP (1) | JP3046318B2 (da) |
| KR (1) | KR970010758B1 (da) |
| CN (1) | CN1102174C (da) |
| AR (1) | AR243935A1 (da) |
| AT (1) | ATE115999T1 (da) |
| AU (1) | AU632993B2 (da) |
| CA (1) | CA1340831C (da) |
| DE (1) | DE3852539T3 (da) |
| DK (1) | DK175956B1 (da) |
| ES (1) | ES2065919T5 (da) |
| FI (1) | FI104562B (da) |
| GR (1) | GR3015374T3 (da) |
| HU (2) | HUT54407A (da) |
| MC (1) | MC2115A1 (da) |
| NO (2) | NO308610B1 (da) |
| NZ (1) | NZ227332A (da) |
| RO (1) | RO114469B1 (da) |
| WO (1) | WO1989005852A1 (da) |
Families Citing this family (177)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019556A (en) * | 1987-04-14 | 1991-05-28 | President And Fellows Of Harvard College | Inhibitors of angiogenin |
| CA1340323C (en) * | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
| US5866701A (en) * | 1988-09-20 | 1999-02-02 | The Board Of Regents For Northern Illinois University Of Dekalb | HIV targeted hairpin ribozymes |
| US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US5624824A (en) * | 1989-03-24 | 1997-04-29 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
| DE4091533T (da) * | 1989-08-31 | 1992-01-30 | ||
| US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
| US5225337A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| DE3933384A1 (de) * | 1989-10-06 | 1991-04-18 | Hoechst Ag | Multifunktionelle rna mit selbstprozessierungsaktivitaet, ihre herstellung und ihre verwendung |
| DE3935473A1 (de) * | 1989-10-25 | 1991-05-02 | Hoechst Ag | Rna mit endonuclease- und antisense-aktivitaet, ihre herstellung und ihre verwendung |
| KR927003044A (ko) * | 1990-01-11 | 1992-12-17 | 크리스토퍼 케이. 미라벨리 | Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법 |
| US5519164A (en) * | 1990-02-01 | 1996-05-21 | Hoechst Aktiengesellschaft | Expression of a multigene RNA having self-splicing activity |
| DE4002885A1 (de) * | 1990-02-01 | 1991-08-08 | Hoechst Ag | Expression einer multigen rna mit self-splicing aktivitaet |
| US5180818A (en) * | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| WO1991018913A1 (en) * | 1990-06-07 | 1991-12-12 | City Of Hope | Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna |
| AU7152191A (en) * | 1990-06-07 | 1991-12-31 | City Of Hope | Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna |
| WO1991019789A1 (en) * | 1990-06-19 | 1991-12-26 | Commonwealth Scientific And Industrial Research Organisation | Endonucleases |
| US6008343A (en) * | 1990-06-19 | 1999-12-28 | Gene Shears Pty. Ltd. | Nucleotide based endonucleases |
| US5246921A (en) * | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
| CA2086105A1 (en) * | 1990-06-26 | 1991-12-27 | Premkumar Reddy | Method for treating leukemias |
| WO1992001786A1 (en) * | 1990-07-26 | 1992-02-06 | Foundation For Research And Technology - Hellas (Fo.R.T.H.) Institute Of Molecular Biology & Biotechnology | Portable ribozyme cassettes, dna sequences containing them, ribozymes encoded by these dna sequences, and compositions containing these ribozymes |
| PL169576B1 (pl) * | 1990-10-12 | 1996-08-30 | Max Planck Gesellschaft | Sposób wytwarzania czasteczki RNA o aktywnosci katalitycznej PL PL |
| NZ241310A (en) * | 1991-01-17 | 1995-03-28 | Gen Hospital Corp | Trans-splicing ribozymes |
| NZ314630A (en) * | 1991-01-17 | 2000-11-24 | Harvard College | Use of trans-splicing ribozymes for genetic modification and cell ablation in a host cell |
| FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| FI913197A0 (fi) | 1991-07-01 | 1991-07-01 | Xyrofin Oy | Nya jaeststammar med reducerad foermaoga att metabolisera xylitol, foerfarande foer bildande av dessa och deras anvaendning vid framstaellning av xylitol. |
| EP0623171A4 (en) * | 1992-01-13 | 1997-02-12 | Univ Duke | ENZYMATIC RNA MOLECULES. |
| EP0592685B1 (en) * | 1992-04-17 | 2001-11-28 | Kirin Beer Kabushiki Kaisha | Plant resistant to two or more viruses and preparation thereof |
| WO1994000012A1 (en) * | 1992-06-29 | 1994-01-06 | Gene Shears Pty. Ltd. | Nucleic acids and methods of use thereof for controlling viral pathogens |
| EP0653488B1 (en) * | 1992-07-02 | 2003-04-09 | Sankyo Company Limited | Looped, hairpin ribozyme |
| US5409823A (en) * | 1992-09-24 | 1995-04-25 | Ciba-Geigy Corporation | Methods for the production of hybrid seed |
| US5864028A (en) * | 1992-11-03 | 1999-01-26 | Gene Shears Pty. Limited | Degradation resistant mRNA derivatives linked to TNF-α ribozymes |
| ZA938208B (en) * | 1992-11-03 | 1995-01-03 | Gene Shears Pty Ltd | TNF-alpha ribozymes and degradation resistant mRNA derivatives linked to TNF-alpha ribozymes |
| JPH08506724A (ja) * | 1992-12-04 | 1996-07-23 | アポロン・インコーポレーテッド | 白血病治療のための化合物および方法 |
| WO1994013833A1 (en) * | 1992-12-04 | 1994-06-23 | Innovir Laboratories, Inc. | Ribozyme amplified diagnostics |
| EP0707638A4 (en) * | 1992-12-04 | 1998-05-20 | Innovir Lab Inc | REGULABLE NUCLEIC ACID FOR THERAPEUTIC USE AND METHODS OF USE THEREOF |
| FR2701960B1 (fr) * | 1993-02-26 | 2002-09-13 | Gene Shears Pty Ltd | Polyribozyme apte à conférer, aux plantes, une résistance aux virus et plantes résistantes produisant ce polyribozyme. |
| US5817635A (en) * | 1993-08-09 | 1998-10-06 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
| WO1995010608A1 (en) * | 1993-10-15 | 1995-04-20 | Foundation For Research And Technology - Hellas (Fo.R.T.H.) | Asymmetric hammerhead ribozymes and nucleotide sequences for their construction |
| US5869248A (en) * | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
| US5998193A (en) * | 1994-06-24 | 1999-12-07 | Gene Shears Pty., Ltd. | Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof |
| US6350934B1 (en) | 1994-09-02 | 2002-02-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid encoding delta-9 desaturase |
| US5683873A (en) * | 1995-01-13 | 1997-11-04 | Innovir Laboratories, Inc. | EGS-mediated inactivation of target RNA |
| US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| WO1996040906A1 (en) | 1995-06-07 | 1996-12-19 | Commonwealth Scientific And Industrial Research Organisation | Optimized minizymes and miniribozymes and uses thereof |
| US6010904A (en) * | 1995-06-07 | 2000-01-04 | The General Hospital Corporation | Cell ablation using trans-splicing ribozymes |
| US6004806A (en) * | 1995-06-07 | 1999-12-21 | Commonwealth Scientific And Industrial Research Organization | Optimized minizymes and miniribozymes and uses thereof |
| MX9800454A (es) * | 1995-07-13 | 1998-04-30 | Ribozyme Pharm Inc | Composiciones y metodo para modulacion de expresion de genes en las plantas. |
| US5824519A (en) * | 1995-11-08 | 1998-10-20 | Medical University Of South Carolina | Tissue-specific and target RNA-specific ribozymes |
| US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
| US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
| WO1998006837A1 (en) * | 1996-08-16 | 1998-02-19 | Yale University | Phenotypic conversion of drug-resistant bacteria to drug-sensitivity |
| US6610478B1 (en) | 1996-08-16 | 2003-08-26 | Yale University | Phenotypic conversion of cells mediated by external guide sequences |
| US6884430B1 (en) | 1997-02-10 | 2005-04-26 | Aventis Pharma S.A. | Formulation of stabilized cationic transfection agent(s) /nucleic acid particles |
| US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| CA2286895C (en) | 1997-04-15 | 2010-07-13 | Commonwealth Scientific And Industrial Research Organisation | Plant fatty acid epoxygenase genes and uses therefor |
| US7589253B2 (en) | 1997-04-15 | 2009-09-15 | Commonwealth Scientific And Industrial Research Organisation | Fatty acid epoxygenase genes from plants and uses therefor in modifying fatty acid metabolism |
| DE69826124T3 (de) | 1997-06-30 | 2007-10-11 | Institut Gustave Roussy | Verabreichung der nukleinsäure in den quergestreiften muskel |
| AU754803B2 (en) | 1997-09-16 | 2002-11-28 | Cropdesign N.V. | Cyclin-dependent kinase inhibitors and uses thereof |
| DE19741375C2 (de) * | 1997-09-19 | 1999-10-21 | Max Planck Gesellschaft | Transgene Pflanzen, deren oberirdische Teile früher reifen und vollständig absterben |
| EP1019082B2 (en) | 1997-10-02 | 2008-06-04 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| EP1032595B1 (en) | 1997-11-18 | 2011-05-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nucleic acids involved in the responder phenotype and applications thereof |
| US6013447A (en) * | 1997-11-21 | 2000-01-11 | Innovir Laboratories, Inc. | Random intracellular method for obtaining optimally active nucleic acid molecules |
| CZ295108B6 (cs) | 1998-03-20 | 2005-05-18 | Benitec Australia Ltd | Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US6248525B1 (en) | 1998-03-30 | 2001-06-19 | Yale University | Method for identifying essential or functional genes |
| WO1999067400A1 (en) | 1998-06-24 | 1999-12-29 | Musc Foundation For Research Development | Tissue-specific and target rna-specific ribozymes |
| DE19836098A1 (de) | 1998-07-31 | 2000-02-03 | Hoechst Schering Agrevo Gmbh | Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zur Herstellung der Pflanzen, ihre Verwendung sowie die modifizierte Stärke |
| JP2002527066A (ja) | 1998-10-15 | 2002-08-27 | カイロン コーポレイション | 転移性乳癌および結腸癌調節遺伝子 |
| AU773808B2 (en) * | 1998-11-09 | 2004-06-10 | Bayer Cropscience Aktiengesellschaft | Nucleic acid molecules from rice and their use for the production of modified starch |
| WO2000029592A2 (en) | 1998-11-12 | 2000-05-25 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Chimeric promoters capable of mediating gene expression in plants upon pathogen infection and uses thereof |
| EP1141331B1 (en) | 1998-12-16 | 2008-09-17 | Novartis Vaccines and Diagnostics, Inc. | HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE) |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| AUPQ005299A0 (en) | 1999-04-29 | 1999-05-27 | Commonwealth Scientific And Industrial Research Organisation | Novel genes encoding wheat starch synthases and uses therefor |
| AU778695B2 (en) | 1999-07-20 | 2004-12-16 | Ges. Fur Erwerb Und Verwertung Von Schutzrechten-Gvs Mbh | Novel method for the generation and selection of transgenic linseed/flax plants |
| US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
| CA2416289C (en) | 2000-07-21 | 2012-12-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| AU1480402A (en) | 2000-11-09 | 2002-05-21 | Commw Scient Ind Res Org | Barley with reduced SSII activity and starch containing products with a reduced amylopectin content |
| ITMI20011364A1 (it) * | 2001-06-28 | 2002-12-28 | Metapontum Agrobios S C R L | Robozima hammerhead specifico per la stearoyl-acp desaturesi di piante oleaginose differenti |
| CN101926824A (zh) | 2001-07-10 | 2010-12-29 | 强生和强生研究有限公司 | 用于遗传修饰造血祖细胞的方法和这些被修饰细胞的应用 |
| US7994144B2 (en) | 2001-07-10 | 2011-08-09 | Johnson & Johnson Research Pty, Limited | Process for the preparation of a composition of genetically modified hematopoietic progenitor cells |
| US8022272B2 (en) | 2001-07-13 | 2011-09-20 | Sungene Gmbh & Co. Kgaa | Expression cassettes for transgenic expression of nucleic acids |
| FR2829136B1 (fr) | 2001-08-29 | 2006-11-17 | Aventis Pharma Sa | Derives lipidiques d'aminoglycosides |
| US7456335B2 (en) | 2001-09-03 | 2008-11-25 | Basf Plant Science Gmbh | Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants |
| EP1427856B1 (en) | 2001-09-18 | 2011-05-11 | Carnegie Institution Of Washington | Fusion proteins useful for detecting analytes |
| WO2003051314A2 (en) | 2001-12-18 | 2003-06-26 | Medallion Biomedical, Llc | Antibiotic compounds |
| US20040005546A1 (en) | 2002-02-28 | 2004-01-08 | Oncolytics Biotech Inc. | Use of ribozymes in the detection of adventitious agents |
| DE10212892A1 (de) | 2002-03-20 | 2003-10-09 | Basf Plant Science Gmbh | Konstrukte und Verfahren zur Regulation der Genexpression |
| EP1900827A3 (en) | 2002-05-21 | 2008-04-16 | Bayer HealthCare AG | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia |
| CA2542171C (en) | 2002-06-26 | 2015-12-15 | Abbott Gmbh & Co. Kg | Modulators and modulation of the interaction between rgm and neogenin |
| EP1527183B1 (de) | 2002-07-26 | 2008-08-20 | BASF Plant Science GmbH | Neue selektionsverfahren |
| EP1572976B1 (en) | 2002-11-21 | 2010-09-15 | Celltech R & D, Inc. | Modulating immune responses |
| PT1578973E (pt) | 2002-12-19 | 2008-10-16 | Bayer Cropscience Ag | Células de plantas e plantas que sintetizam um amido com uma melhor viscosidade final |
| PL1625166T3 (pl) | 2003-05-12 | 2015-08-31 | Helion Biotech Aps | Przeciwciała przeciwko masp-2 |
| US7812221B2 (en) | 2003-06-30 | 2010-10-12 | Commonwealth Scientific And Industrial Research Organization | Wheat with altered branching enzyme activity and starch and starch containing products derived therefrom |
| EP1892306A3 (en) | 2003-10-06 | 2008-06-11 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
| US7604947B2 (en) | 2004-06-09 | 2009-10-20 | Cornell Research Foundation, Inc. | Detection and modulation of cancer stem cells |
| ES2601497T3 (es) | 2004-06-10 | 2017-02-15 | Omeros Corporation | Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2 |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP1763582B1 (en) | 2004-07-08 | 2014-12-10 | DLF - Trifolium A/S | Means and methods for controlling flowering in plants |
| CA2834275A1 (en) | 2004-08-02 | 2006-02-09 | Basf Plant Science Gmbh | Method for isolation of transcription termination sequences |
| EP1794304B1 (en) | 2004-09-24 | 2013-06-19 | BASF Plant Science GmbH | Plant cells and plants with increased tolerance to environmental stress |
| JP5638736B2 (ja) | 2004-12-30 | 2014-12-10 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | 腸の健康を改善する方法および手段 |
| EP1707632A1 (de) | 2005-04-01 | 2006-10-04 | Bayer CropScience GmbH | Phosphorylierte waxy-Kartoffelstärke |
| ES2542501T3 (es) | 2005-09-30 | 2015-08-06 | Abbvie Deutschland Gmbh & Co Kg | Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso |
| CA2628505A1 (en) | 2005-11-08 | 2007-05-18 | Basf Plant Science Gmbh | Use of armadillo repeat (arm1) polynucleotides for obtaining resistance to pathogens in plants |
| EP1979484B1 (en) | 2006-01-12 | 2014-03-19 | BASF Plant Science GmbH | Use of stomatin (stm1) polynucleotides for achieving a pathogen resistance in plants |
| AU2007299219A1 (en) | 2006-04-05 | 2008-03-27 | Metanomics Gmbh | Process for the production of a fine chemical |
| EP2030021B1 (en) | 2006-05-18 | 2012-11-21 | Andreas Reichert | Method for diagnosing mitochondrial dysfunction |
| US8383597B2 (en) | 2006-05-25 | 2013-02-26 | Cornell Research Foundation, Inc. | G proteins in tumor growth and angiogenesis |
| CN101600808B (zh) | 2006-10-06 | 2014-07-09 | 强生研究有限公司 | 分子开关及其使用方法 |
| WO2008087141A2 (en) | 2007-01-15 | 2008-07-24 | Basf Plant Science Gmbh | Use of subtilisin (rnr9) polynucleotides for achieving a pathogen resistance in plants |
| EP2074219B1 (en) | 2007-02-16 | 2013-11-20 | BASF Plant Science GmbH | Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants |
| CA2681650C (en) | 2007-03-27 | 2016-11-22 | Omeros Corporation | The use of pde7 inhibitors for the treatment of movement disorders |
| CA2687635A1 (en) | 2007-05-22 | 2008-11-27 | Basf Plant Science Gmbh | Plant cells and plants with increased tolerance and/or resistance to environmental stress and increased biomass production-ko |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| EP2040075A1 (en) | 2007-09-24 | 2009-03-25 | Julius-Maximilians-Universität Würzburg | Compounds and markers for surface-enhanced raman scattering |
| MX2010006519A (es) | 2007-12-14 | 2010-10-15 | Amgen Inc | Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina. |
| AU2008340002A1 (en) | 2007-12-21 | 2009-07-02 | Basf Plant Science Gmbh | Plants with increased yield (KO NUE) |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| EP2100962A1 (en) | 2008-03-12 | 2009-09-16 | Biogemma | Plants having improved resistance to pathogens |
| US10517839B2 (en) | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| US8790664B2 (en) | 2008-09-05 | 2014-07-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Multimodular assembly useful for intracellular delivery |
| EP2184351A1 (en) | 2008-10-30 | 2010-05-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Polynucleotides encoding caryophyllene synthase and uses thereof |
| ES2363358B1 (es) | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| DE112010003162T5 (de) | 2009-04-22 | 2012-08-16 | Basf Plant Science Company Gmbh | Gesamtsamen-spezifischer Promotor |
| EP2475367A1 (en) | 2009-09-10 | 2012-07-18 | Centre National De La Recherche Scientifique | NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES |
| EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
| CA2777845C (en) | 2009-10-16 | 2017-08-01 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| CN102812014B (zh) | 2009-10-30 | 2016-01-20 | 多美恩医疗公司 | 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途 |
| EP2322149A1 (en) | 2009-11-03 | 2011-05-18 | Universidad del Pais Vasco | Methods and compositions for the treatment of ischemia |
| SG181563A1 (en) | 2009-12-08 | 2012-07-30 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
| US8476485B2 (en) | 2010-06-24 | 2013-07-02 | Academia Sinica | Non-human animal model for amyotrophic lateral sclerosis (ALS) with loss-of-TDP-43 function |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| CN103547267A (zh) | 2010-11-08 | 2014-01-29 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2012139081A2 (en) | 2011-04-08 | 2012-10-11 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| US20150017091A1 (en) | 2011-08-18 | 2015-01-15 | Cornell University | Detection and treatment of metastatic disease |
| WO2013039880A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biomarkers and therapeutic targets of hepatocellular cancer |
| CA2859564C (en) | 2011-12-16 | 2020-04-14 | Board Of Trustees Of Michigan State University | P-coumaroyl-coa:monolignol transferase |
| RU2644337C2 (ru) | 2012-01-27 | 2018-02-08 | Эббви Дойчланд Гмбх Унд Ко. Кг | Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов |
| WO2013138463A1 (en) | 2012-03-14 | 2013-09-19 | University Of Central Florida Research Foundation, Inc. | Neurofibromatoses therapeutic agents and screening for same |
| EP2666775A1 (en) | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| WO2014127835A1 (en) | 2013-02-22 | 2014-08-28 | Christian-Albrechts-Universität Zu Kiel | Plant-derived resistance gene |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| IL283373B1 (en) | 2013-10-17 | 2024-04-01 | Omeros Corp | Pharmaceutical preparations containing MASP-2 suppressors to suppress MASP-2-dependent complement activation and related diseases |
| NZ721036A (en) | 2013-12-18 | 2023-07-28 | Grains Res & Dev Corp | Lipid comprising long chain polyunsaturated fatty acids |
| EP3160482A4 (en) | 2014-06-27 | 2018-02-14 | Commonwealth Scientific and Industrial Research Organisation | Lipid comprising docosapentaenoic acid |
| EP3000814A1 (en) | 2014-09-26 | 2016-03-30 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| AU2016354117B2 (en) | 2015-11-09 | 2019-11-28 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| UA127339C2 (uk) | 2016-01-05 | 2023-07-26 | Юніверсіті Оф Лестер | СПОСІБ ПРОФІЛАКТИКИ АБО ЗМЕНШЕННЯ УРАЖЕННЯ НИРОК У СУБ'ЄКТА, ЩО СТРАЖДАЄ НА СТЕРОЇДЗАЛЕЖНУ ІМУНОГЛОБУЛІН-А-НЕФРОПАТІЮ (IgAN) |
| SG10202009886SA (en) | 2016-03-31 | 2020-11-27 | Omeros Corp | Methods for inhibiting angiogenesis in a subject in need thereof |
| JP6995783B2 (ja) | 2016-05-26 | 2022-02-04 | ヌンヘムス、ベスローテン、フェンノートシャップ | 種なし果実を実らせる植物 |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| DK3565891T3 (da) | 2017-01-09 | 2023-07-24 | Whitehead Inst Biomedical Res | Fremgangsmåder til ændring af genekspression ved forstyrrelse af transkriptionsfaktor-multimere, der strukturerer regulatoriske sløjfer |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| US10883089B2 (en) | 2017-04-04 | 2021-01-05 | Wisconsin Alumni Research Foundation | Feruloyl-CoA:monolignol transferases |
| US10883090B2 (en) | 2017-04-18 | 2021-01-05 | Wisconsin Alumni Research Foundation | P-coumaroyl-CoA:monolignol transferases |
| EP3655015B1 (en) | 2017-07-17 | 2024-02-21 | The Regents of the University of Colorado | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| TW202402809A (zh) | 2017-08-15 | 2024-01-16 | 美商歐米諾斯公司 | 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法 |
| EP3676376A2 (en) | 2017-08-30 | 2020-07-08 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR20200121782A (ko) | 2017-10-16 | 2020-10-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| US11291176B2 (en) | 2018-06-15 | 2022-04-05 | Nunhems B.V. | Seedless watermelon plants comprising modifications in an ABC transporter gene |
| US11981904B2 (en) | 2018-11-09 | 2024-05-14 | Wisconsin Alumni Research Foundation | BAHD acyltransferases |
| BR112021018606A2 (pt) | 2019-03-19 | 2021-11-23 | Harvard College | Métodos e composições para editar sequências de nucleotídeos |
| JP2023504543A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
| CN116096378A (zh) | 2020-08-10 | 2023-05-09 | 诺华股份有限公司 | 视网膜变性疾病的治疗 |
| WO2024038089A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
| WO2024042160A1 (en) | 2022-08-26 | 2024-02-29 | Mitodicure Gmbh | Use of a therapeutic agent with sodium-hydrogen antiporter 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) * | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| DE3642623A1 (de) * | 1986-12-13 | 1988-06-23 | Burbach & Bender Ohg | Gasspuelstein fuer metallurgische gefaesse |
| DE3939771A1 (de) * | 1989-12-01 | 1991-06-06 | Behringwerke Ag | Verfahren zur biologischen inaktivierung von nukleinsaeuren |
-
1988
- 1988-12-14 RO RO145344A patent/RO114469B1/ro unknown
- 1988-12-14 NZ NZ227332A patent/NZ227332A/xx unknown
- 1988-12-14 WO PCT/AU1988/000478 patent/WO1989005852A1/en active IP Right Grant
- 1988-12-14 CA CA000585845A patent/CA1340831C/en not_active Expired - Fee Related
- 1988-12-14 HU HU89382A patent/HUT54407A/hu unknown
- 1988-12-14 KR KR1019890701528A patent/KR970010758B1/ko not_active IP Right Cessation
- 1988-12-14 AU AU28007/89A patent/AU632993B2/en not_active Expired
- 1988-12-14 EP EP94107862A patent/EP0640688A1/en not_active Withdrawn
- 1988-12-14 ES ES88311816T patent/ES2065919T5/es not_active Expired - Lifetime
- 1988-12-14 JP JP1500279A patent/JP3046318B2/ja not_active Expired - Lifetime
- 1988-12-14 EP EP88311816A patent/EP0321201B2/en not_active Expired - Lifetime
- 1988-12-14 DE DE3852539T patent/DE3852539T3/de not_active Expired - Lifetime
- 1988-12-14 AT AT88311816T patent/ATE115999T1/de not_active IP Right Cessation
- 1988-12-14 AR AR88312737A patent/AR243935A1/es active
- 1988-12-14 MC MC882115D patent/MC2115A1/xx unknown
- 1988-12-15 CN CN88108572A patent/CN1102174C/zh not_active Expired - Lifetime
-
1990
- 1990-06-12 DK DK199001433A patent/DK175956B1/da not_active IP Right Cessation
- 1990-06-12 FI FI902923A patent/FI104562B/fi not_active IP Right Cessation
- 1990-06-14 NO NO902661A patent/NO308610B1/no unknown
-
1995
- 1995-03-13 GR GR940403895T patent/GR3015374T3/el unknown
- 1995-06-22 HU HU95P/P00362P patent/HU211891A9/hu unknown
-
2000
- 2000-01-25 NO NO20000369A patent/NO312105B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO308610B1 (no) | Ribozymer for anvendelse som midler for behandling av planter, fremgangsmÕte for fremstilling derav, og preparater omfattende slike ribozymer | |
| US5254678A (en) | Ribozymes | |
| US5543508A (en) | Ribozymes | |
| Steinecke et al. | Expression of a chimeric ribozyme gene results in endonucleolytic cleavage of target mRNA and a concomitant reduction of gene expression in vivo. | |
| US5874414A (en) | Trans-splicing ribozymes | |
| US5866384A (en) | Cell ablation using trans-splicing ribozymes | |
| RU2144080C1 (ru) | Рибозим, способ инактивации рнк-мишени, способ получения рибозима | |
| Tabler | Antisense RNA in plants: A tool for analysis and suppression of gene function | |
| IL88683A (en) | Ribozymes their production and pharmaceutical compositions containing them | |
| AU653787C (en) | Cell ablation using trans-splicing ribozymes |